Johnson & Johnson (NYSE:JNJ) has received the U.S. FDA approval to expand the label of its dual-acting monoclonal antibody Tremfya (guselkumab) to include adults with moderately to severely active ...

Notable news about inflammatory bowel disease (IBD) in 2024 included a study evaluating loss of response to tumor necrosis factor (TNF) blockers, new FDA approvals, problems with placebos, and ...

Dr. Madiha Aziz with St. Joseph's/Candler sat down with WSAV to talk about the symptoms, treatment and stigma surround the ...

Patients with inflammatory bowel disease often have to wait a long time to find the right medicine. But the methods of a large interdisciplinary research team offer hope. IBD is the common ...

A new study from researchers at the Alliance for Clinical Trials in Oncology (Alliance) shows that patients with stage III ...